BISORB®Drug-Eluting Sinus Absorbable Stent System Successfully Registered and Approved in Thailand
Date：2024-06-12 17:28:46
BISORB®Drug-Eluting Sinus Absorbable Stent System Successfully Registered and Approved in Thailand
Puyi (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Puyi") announced on September 7, 2023, that its BISORB®Drug-Eluting Sinus Absorbable Stent System has been successfully registered and approved by the Thai authorities. It is registered in Thailand as the "BISORB Drug-Eluting Sinus Absorbable Stent System." This product has passed the rigorous review of the Thai Food and Drug Administration (TFDA) and fully meets the market access requirements for medical devices in Thailand, with a registration validity period extending to September 7, 2028.
This product is specifically designed for patients with chronic rhinosinusitis (CRS) who undergo endoscopic sinus surgery (ESS). Its main functions include supporting and separating the wound surface during and after surgery, fixing and repairing the mucosal flap, and slowly releasing hormones to control edema, prevent adhesion, ensure smooth drainage, continuously fight inflammation at the target site, and promote healing. The Xiangtong Fully Biodegradable Sinus Drug-Eluting Stent System consists of a stent and a delivery system, and it has been sterilized using electron beam irradiation to ensure safety and hygiene during use.
Puyi stated that it will continue to invest in product innovation and technological research and development, aiming to provide support and assistance to more overseas patients undergoing ESS surgery and bring benefits to more local patients.
